Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
1.11 (USD) • At close April 30, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 1.028 | 0 | 0 | 2.717 | 0.462 | 0.979 |
| Cost of Revenue
| 0 | 0.822 | 1.312 | 0 | 0 | 0 |
| Gross Profit
| 1.028 | -0.822 | -1.312 | 2.717 | 0.462 | 0.979 |
| Gross Profit Ratio
| 1 | 0 | 0 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 26.682 | 39.624 | 36.607 | 26.482 | 12.044 | 24.579 |
| General & Administrative Expenses
| 23.946 | 26.475 | 26.844 | 27.834 | 4.962 | 3.465 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 23.946 | 26.475 | 26.844 | 27.834 | 4.962 | 3.465 |
| Other Expenses
| 3.714 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 54.342 | 66.099 | 63.451 | 54.316 | 17.006 | 28.044 |
| Operating Income
| -53.314 | -66.099 | -63.451 | -51.599 | -16.544 | -27.065 |
| Operating Income Ratio
| -51.862 | 0 | 0 | -18.991 | -35.81 | -27.646 |
| Total Other Income Expenses Net
| 23.296 | -1.784 | 0.177 | -1.448 | -0.124 | 0.478 |
| Income Before Tax
| -30.018 | -67.883 | -63.274 | -53.047 | -16.668 | -26.587 |
| Income Before Tax Ratio
| -29.2 | 0 | 0 | -19.524 | -36.078 | -27.157 |
| Income Tax Expense
| 0 | 0 | 0.07 | 0.041 | 0.035 | 0.01 |
| Net Income
| -30.018 | -33.97 | -63.344 | -53.088 | -16.703 | -26.597 |
| Net Income Ratio
| -29.2 | 0 | 0 | -19.539 | -36.154 | -27.168 |
| EPS
| -1.05 | -1.33 | -2.66 | -2.69 | -0.85 | -1.35 |
| EPS Diluted
| -1.05 | -1.33 | -2.66 | -2.69 | -0.85 | -1.35 |
| EBITDA
| -50.523 | -65.277 | -60.891 | -52.084 | -15.955 | -26.013 |
| EBITDA Ratio
| -49.147 | 0 | 0 | -19.17 | -34.535 | -26.571 |